M
Minghua Ge
Researcher at Chinese Academy of Sciences
Publications - 36
Citations - 217
Minghua Ge is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 6 publications receiving 61 citations. Previous affiliations of Minghua Ge include Bengbu Medical College.
Papers
More filters
Journal ArticleDOI
2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma.
Ming Gao,Minghua Ge,Qinghai Ji,Ruochuan Cheng,Hankui Lu,Haixia Guan,Li Gao,Zhuming Guo,Tao Huang,Xiaoming Huang,Xiaoming Li,Yansong Lin,Qinjiang Liu,Xin Ni,Yi Pan,Jianwu Qin,Zhongyan Shan,Hui Sun,Xudong Wang,Zhengang Xu,Yang Yu,Daiwei Zhao,Naisong Zhang,Sheng Zhang,Ying Zheng,Jingqiang Zhu,Dapeng Li,Xiangqian Zheng +27 more
TL;DR: Department of Head and Neck Tumor Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin.
Journal ArticleDOI
Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
Dapeng Li,Yihebali Chi,Xiaohong Chen,Minghua Ge,Minghua Ge,Yuan Zhang,Zhuming Guo,Jun Wang,Jie Chen,Jiewu Zhang,Ying Cheng,Zhendong Li,Hui Liu,Jianwu Qin,Jingqiang Zhu,Ruochuan Cheng,Zhengang Xu,Xiangqian Zheng,Pingzhang Tang,Ming Gao +19 more
TL;DR: Anlotinib as discussed by the authors is a multitarget tyrosine kinase inhibitor targeting VEGFR, PDGFR, FGFR, and c-kit targeting locally advanced or metastatic thyroid cancer.
Journal ArticleDOI
Exploration of nanozymes in viral diagnosis and therapy
Miyoung Lee,Hongwei Liao,Qiyue Wang,Jieun Han,Jun-Hyeok Han,Hatou Shin,Minghua Ge,Woo Bong Park,Fangyuan Li +8 more
TL;DR: Nanozyme can provide a novel nanozyme‐based antiviral therapeutic regime with broader availability and generalizability that are keys to fighting a pandemic such as COVID‐19.
Journal ArticleDOI
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.
Xiangqian Zheng,Zhengang Xu,Qinghai Ji,Minghua Ge,Feng Shi,Jianwu Qin,Feng Wang,Guang Chen,Yuan Zhang,Rui Huang,Jian Tan,Tao Huang,Sijin Li,Zhongwei Lv,Yansong Lin,Zhuming Guo,Tomoki Kubota,Takuya Suzuki,Hiroki Ikezawa,Ming Gao +19 more
TL;DR: In this paper, Lenvatinib at a starting dose of 24 mg/day significantly improved progression-free survival and objective response rate in Chinese patients with RR-DTC versus placebo.
Journal ArticleDOI
Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: A multicenter, randomized, double-blind, placebo-controlled phase IIB trial.
Dapeng Li,Ping Zhang Tang,Xiaohong Chen,Minghua Ge,Yuan Zhang,Zhuming Guo,Jun Wang,Feng Shi,Jiewu Zhang,Ying Cheng,Zhendong Li,Hui Liu,Jianwu Qin,Rui Huang,Ruochuan Cheng,Zhengang Xu,Yihebali Chi,Xiangqian Zheng,Ming Gao +18 more
TL;DR: Anlotinib is a novel multi-target TKI, inhibiting tumor angiogenesis and proliferative signaling, and a previous single-arm phase 2 ALTN/MTC trial (NCT01874873) showed encouraging results.